Shanghai Fudan Zhangjiang Bio Pharmaceutical Co (DE:FDY) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. has announced the successful enrollment of the first patient in a Phase I clinical trial for its new drug, FZ-AD005, targeting advanced solid tumors, including small cell lung cancer and prostatic cancer. The drug is based on the company’s proprietary BB05 platform and is a first-in-China ADC that employs topoisomerase inhibitors to destroy tumor cells. Investors are advised to consider the high-risk nature of pharmaceutical development and to pay attention to investment risks, as the company continues its research and development efforts.
For further insights into DE:FDY stock, check out TipRanks’ Stock Analysis page.
